Triple-drug regimen lowers A1C, treatment failure in new-onset diabetes

10/8/2013 | InternalMedicineNews.com (free registration)

Patients with new-onset type 2 diabetes who had initial triple-drug treatment of metformin, exenatide and pioglitazone attained a mean A1C of 5.9% at two years, compared with 6.6% in those who received conventional stepwise treatment, a study indicated. Researchers also found the triple-drug regimen was associated with an 84% reduction in two-year treatment failure rates compared with standard therapy. The results were presented at the European Association for the Study of Diabetes meeting.

View Full Article in:

InternalMedicineNews.com (free registration)

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Director, Litigation & Investigations EMEA
Gilead Sciences
Stockely Park
Assistant General Counsel/Senior Corporate Counsel
Genentech
South San Francisco, CA
Senior Analyst Compliance
Edwards Lifesciences
Irvine, CA
Legal Counsel
Alcon
Fort Worth, TX
Director, Senior Legal Counsel
Alcon
Fort Worth, TX